In spite of the well-known contribution of angiotensin II (Ang II) in the pathogenesis of Goldblatt two-kidney one clip (G2K1C) hypertension, the importance of other Ang peptides, such as Ang III, Ang IV or Ang 2-10, is scarcely understood. The functional status of these peptides depends on the action of several aminopeptidases called angiotensinases. The metabolism of Ang III to Ang IV by aminopeptidase M (AlaAP) and of Ang I to Ang 2-10 by aspartyl aminopeptidase (AspAP) was evaluated in the renal cortex and medulla of normotensive (Sham-operated) and hypertensive (G2K1C) rats, treated or not with the AT 1 receptor antagonist valsartan. The results demonstrated a highly significant increase of membrane-bound (MEMB) AlaAP in the cortex of the non-ischemic kidney of G2K1C rats compared with the kidney of normal rats and with the clipped kidney of G2K1C rats. This suggests an increased formation of Ang IV in the non-clipped kidney of G2R1C rats. Valsartan reduced MEMB AlaAP and AspAP activities in the renal cortex of normotensive and in the clipped kidney of hypertensive rats. The reduced metabolism of Ang III may prolong its half-life in valsartan-treated animals. These results suggest a role for AlaAP in renovascular hypertension. In addition, the higher AspAP activity of the renal cortex compared to medulla reflects its relative functional difference between both locations.
Introduction
The renin-angiotensin system (RAS) is an important regulator of blood pressure (BP) and hydro-electrolytic balance. Until recently, through its action on the AT 1 receptor, angiotensin II (Ang II) was considered the main peptide involved in these functions. However, other peptides of this system such as Ang III, Ang IV, Ang 2-10, Ang 1-7 or Ang 1-9 appear also important factors in the regulatory role of the RAS. For example, Ang III is a less potent vasoconstrictor than Ang II [13] ; it stimulates aldosterone secretion and is a neuronal stimulus [3] . Its affinity for the AT 1 and AT 2 receptors is 3.7 ± 0.7 nmol and 3.1 ± 0.06 nmol, using rat vascular smooth-muscle cells (SMC) and human uterus (HU), respectively [8] . A similar order of potency has been reported in guinea pig liver membrane [9] . The affinity of Ang IV for the AT 1 and AT 2 receptors was small using SMC and HU (0.26 and 0.06 mol, respectively) [8] . Using brain membranes, Ang IV was also reported to have weak affinity for the Ang II receptor [2] , Ang IV has been suggested to play a role in regulating local blood flows [5] and Ang 2-10 seems to have some opposite actions to Ang II [18] . The present hypothesis considers a coordinated action of the different peptides of the system.
The RAS has a pivotal role in the development and maintenance of Goldblatt two-kidney one clip (G2K1C) hypertension: it increases plasmatic and tissue Ang II levels in both clipped and non-clipped kidneys [16] . In this model of hypertension, the non-clipped kidney is renin depleted but the intrarenal Ang II levels are not suppressed and Ang II concentrations in proximal tubular fluid remain high [20] . This could stimulate proximal tubular reabsorption rate, which may contribute to the development and maintenance of hypertension by maintaining an inappropriately high sodium reabsorption rate even at elevated arterial pressure [4] . Clipped and non-clipped kidneys show a slight reduction of aminopeptidase A (glutamyl-aminopeptidase, GluAP, Ang II-degrading enzyme) expression in cortical homogenates of G2K1C animals. This reduction may also contribute to the maintenance of hypertension in facilitating the tubular reabsorptive effects of Ang II [21, 29] . In addition, vasopressin-degrading activity was reduced in the renal cortex and medulla of G2K1C hypertensive animals, which may facilitate the tubular effects of vasopressin, enhancing sodium and water reabsorption and thus contributing to the maintenance of hypertension [21] .
The contribution of angiotensin peptides other than Ang II, such as Ang 2-10, Ang III or Ang IV in the development and maintenance of G2K1C hypertension is not well understood. Ang II production is mainly the result of the action of renin and ACE. However, the production of the other active peptides of RAS, as well as their degradation, depends on several proteolytic enzymes called angiotensinases. The study of the behavior of these enzymes, in physiological and pathological conditions, is important to better understand the role of the RAS in the regulation of BP. Activation of cell membrane-bound receptors is necessary for the physiological actions of peptides and their subsequent metabolism by membrane-bound peptidases is a major mechanism for the regulation of their functionality. However, the increase of intrarenal Ang II is not only due to an increase of the endogenous production but also to an AT 1 receptor-mediated internalization of circulating Ang II [19] . Therefore, the metabolism of Ang II by soluble intracellular proteolytic enzymes may also contribute to the disposal of Ang II and derived peptides. Recently, we have reported the effect of G2K1C hypertension on the soluble and membrane-bound enzymes involved in the renal metabolism of Ang II (GluAP) and vasopressin (cystinyl aminopeptidase) [21] . Here we report the effect of selective AT 1 receptor blockade with valsartan on the behavior of soluble and membrane-bound alanyl aminopeptidase (AlaAP, APM) and aspartyl aminopeptidase (AspAP) activities in the renal cortex and medulla of normotensive (Sham-operated) and G2K1C hypertensive rats. Both angiotensinases have been involved in the metabolism of Ang III to Ang IV [26] and of Ang I to Ang 2-10 [27], respectively. According to the experimental design, the potential comparisons are: MEMB versus SOL activities, cortex versus medulla, clipped versus non-clipped kidney, AlaAP versus AspAP activities, Sham versus G2K1C animals and vehicle versus valsartan.
Materials and methods
Initially, 40 male Wistar rats (200-250 g) were randomly divided into two groups: G2K1C (G) and Sham-operated (S). Placing a 0.2-mm silver clip on the left renal artery under ether anesthesia-induced G2K1C hypertension. The right kidney was left untouched. Rats subjected to a Sham operation were used as controls. Throughout the experiment, animals were monitored for systolic blood pressure (SBP) and water intake (WI). Three weeks after surgery, G and S were, respectively, divided into two additional subgroups: (1) Sham-operated + vehicle (SVCtl), (2) Sham-operated + valsartan (SVs), (3) G2K1C + vehicle (GVCtl), and (4) G2K1C + valsartan (GVs). At the time of randomization, SBP was 126 ± 2 mmHg in SVCtl, 130 ± 1 mmHg in SVs, 167 ± 9 mmHg in GVCtl, and 167 ± 8 mmHg in GVs. WI was 37 ± 2 ml per day in SVCtl, 36 ± 2 ml per day in SVs, 54 ± 4 ml per day in GVCtl, and 53 ± 4 ml per day in GVs. Valsartan (Novartis Pharma AG) (20 mg/kg per day) was administered in drinking water to groups 2 and 4 starting 3 weeks after surgery and pursued for 3 weeks. The dose of valsartan was chosen based on its antihypertensive effects in renal hypertensive rats [6] . The effect of the treatment on SBP and WI has been reported previously [21] . SBP was measured weekly by tail-cuff plethysmography (LE 5001-Pressure Meter, Letica SA, Barcelona, Spain) in trained unanesthetized animals. To adapt the animals to the procedure, BP was repeatedly measured prior the beginning of the investigation during the 6 weeks following the induction of hypertension. The rats were placed in plastic holders and kept warm (37 • C) for each recording session. At least seven determinations were made at every session, and the mean of the lowest three values within a range of 5 mmHg was recorded as the SBP level.
At the end of the study, the surviving animals (SVCtl = 8, SVs = 9, GVCtl = 8, GVs = 10) were perfused with saline through the left cardiac ventricle under equithensin anesthesia (2 ml/kg body weight) (equithensin contained: 42.5 g/l chloralhydrate, 0.162 l/l nembutal ® , 0.396 l/l propylenglycol and 21.3 g/l magnesium sulfate in distilled water). Samples from renal cortex and medulla of clipped and non-clipped kidneys were quickly removed and cooled in dry ice. From these samples we obtained the soluble (SOL) and membrane-bound (MEMB) fraction as previously described [24] . Aminopeptidase activities and proteins were measured in triplicate, respectively, in a fluorometric and colourimetric assay as previously described [24] . The data were analyzed by two-way ANOVA. Post hoc comparisons were made using Tukey's test, and P values below 0.05 were considered significant.
Results
Systolic BP was significantly reduced (P < 0.001) in hypertensive rats treated with valsartan. At the end of the study, SBP was (mean ± S.E.M.) 168 ± 11 mmHg in GVCtl versus 144 ± 6 mmHg in GVs, and 125 ± 2 mmHg in SVCtl versus 124 ± 2 mmHg in SVs. During the 3 weeks of treatment with valsartan, SBP was significantly higher (P < 0.001) in GVCtl than GVs. However, no significant differences were observed between SVs and SVCtl [21] . The results are represented in Figs. 1 and 2 . In comparison with Sham-operated animals, the renal cortex of the clipped kidney of G2K1C animals exhibited a reduction of 50% (P < 0.001) and 13% (P < 0.01) of SOL AlaAP and SOL AspAP, respectively, independently of the treatment with vehicle or valsartan. In contrast, the renal cortex of the non-clipped kidney presented an increase of 75% (P < 0.001) and 15% (P < 0.05) of MEMB AlaAP and MEMB AspAP, respectively, in G2K1C animals treated or not with valsartan, in comparison with Sham-operated animals and with the clipped kidney. SOL AlaAP also increased by 50% (P < 0.001) in the non-clipped compared with the clipped kidney (Fig. 1) .
Valsartan reduces both MEMB AlaAP and AspAP activity in the renal cortex of the clipped kidney. This reduction is by 50% for MEMB AlaAP for both Sham and G2K1C animals and by 34 and 15% for MEMB AspAP for Sham and G2K1C, respectively (Fig. 1) .
In the renal medulla, in comparison with Sham-operated animals, there was a reduction of SOL AlaAP (20%) (P < 0.001) and SOL AspAP (25%) (P < 0.05) in the clipped kidney, and of MEMB AlaAP (40%) (P < 0.01) in the non-clipped kidney independently of the treatment. In comparison with the clipped kidney, the non-clipped demonstrated an increase of SOL AlaAP (10%) (P < 0.05) and SOL AspAP (30%) (P < 0.01). In contrast to the observation in the cortex, valsartan therefore did not affect aminopeptidase activities in the renal medulla (Fig. 2) .
Finally, we observed a highly significant difference for AspAP activity between renal medulla and cortex. SOL and MEMB AspAP activities were, respectively, four-fold (P < 0.001) and five-fold (P < 0.001) higher in the renal cortex than in medulla in all groups studied.
Discussion
In the renal cortex, the most significant results indicate that (in comparison with both the clipped kidney and the normal kidney of Sham-operated rats), the non-clipped kidney had a highly significant increase of MEMB AlaAP activity in G2K1C hypertensive animals treated or not with valsartan ( Fig. 1) . AlaAP metabolizes Ang III to Ang IV [26] . Therefore, the cortex of the non-clipped kidney of G2K1C may have an increased formation of Ang IV. This peptide preferentially binds to the AT 4 receptor, which is mainly distributed in the cortex and outer stripe of the outer medulla [11] . However, the inner medulla of the kidney shows low levels of the AT 4 receptor [12] . Whereas it is accepted that renal infusion of Ang II produces an increase in BP with decreased cortical blood flow and natriuresis, there is controversy on the renal effect of Ang IV. It has been reported that high concentrations of Ang IV are able to activate the AT 1 receptor, inducing renal microvascular constriction which suggest that AT 4 do not exert a vasodilator action in the kidney [30] . In contrast, other authors have reported that infusion of Ang IV increased natriuresis and renal cortical blood flow. Nitric oxide (NO) mediates this effect [5, 10] . The administration of L-NAME decreased the glomerular filtration rate and blood flow in the non-clipped kidney of G2K1C and normal kidney but increased it in the clipped kidney [7] . Therefore, the present data support the hypothesis that the NO-dependent increased blood flow in the cortex of the non-clipped kidney of G2K1C could be due to an increase of Ang IV mediated by the enhanced AlaAP activity. Recently it has been reported that the brain AT 4 receptor is an insulin-regulated membrane aminopeptidase [1] , which had been previously characterized as a cystinyl aminopeptidase (CysAP) [25] . In a recent publication [21] , we have reported the data concerning MEMB CysAP in the present G2K1C animals. Compared with the clipped kidney, this enzymatic activity also increased significantly in the non-clipped kidney of G2K1C. These results parallel with the present data and may be also indicative of an increase of the Ang IV receptor (CysAP activity) in these conditions.
In turn, the cortex of both, the clipped kidney of G2K1C animals and the normal kidney of Sham rats, showed a valsartan-related down-regulation of MEMB AlaAP which may suggests a longer action of Ang III by a decrease of its metabolism. In normal rats, the AT 1 receptor blockade with valsartan increases the renal Ang II and its metabolites, which binds to the unblocked AT 2 receptor. Stimulation of the AT 2 receptor, essentially expressed in the renal cortex [31] , releases bradykinin and mediates NO production [28] . Our results suggest a longer action of Ang III in the cortex of normal kidneys under valsartan treatment. Ang III binds with similar affinity to both AT 1 and AT 2 receptors [8] . Therefore, the increased production of renal bradykinin under AT 1 blockade may also be related with the decrease of MEMB AlaAP in the renal cortex, which reduces the metabolism of Ang III. These results are consistent with the previously reported no modification of aminopeptidase A activity under valsartan treatment in the cortex of normal kidney of Sham rats and in the cortex of the clipped and non-clipped kidney of G2K1C rats [21] . As indicated, the cortex of the clipped kidney of G2K1C animals exhibited a valsartan-related reduction of MEMB AlaAP activity. The inhibition of NO production by L-NAME decreased blood flow in the non-clipped kidney of G2K1C rats. In contrast, the clipped kidney blood flow increased after L-NAME being the systemic pressor effect of L-NAME responsible for these finding. These results indicate that NO plays an important role in systemic and non-clipped kidney hemodynamics in G2K1C hypertension [7] . Valsartan reduced MEMB AlaAP activity in the cortex of both the normal kidney of Sham-operated and the clipped kidney of G2K1C rats but had no effect in the cortex of the non-clipped kidney of G2K1C rats. In contrast, MEMB AlaAP activity increased in the non-clipped kidney of G2K1C rats either receiving vehicle or valsartan. This was not the case in the clipped kidney. Therefore, the local ischemia may differentially determine the renal-RAS response to valsartan treatment. Moreover, local ischemia, or the pressure levels that stand the clipped and non-clipped kidneys of G2K1C rats may also determine the renal-RAS response. The present data are also consistent with those of Madrid et al. [15] , which demonstrated that renal cortical blood flow is modulated by interactions between NO and Ang II. In contrast, renal medullary blood flow appears to be regulated primarily by NO, with little influence of the renal vasoconstrictor systems.
The AT 1 receptor blockade with valsartan also reduced MEMB AspAP activity in the cortex of both, the normal kidney of Sham-operated and in the clipped kidney of G2K1C rats, but had no effect in the cortex of the non-clipped kidney of G2K1C animals. SOL AspAP activity was also reduced in the clipped, but not in the non-clipped kidney of G2K1C rats. The non-clipped kidney did not show variation in ACE activity, whereas the clipped kidney exhibited increased ACE activity compared with Sham-operated rats [17] . Taken together, these results suggest an inhibition of the metabolism of Ang I through the Ang 2-10 pathway favoring Ang II production following treatment with valsartan and the kidney stenosis. SOL AlaAP activity decreased only in the clipped kidney of G2K1C rats. This suggests a lower metabolism of Ang III in the cortex of the clipped kidney. It is therefore proposed, that the increase of intrarenal Ang II is not only due to an increase of the endogenous production and to an AT 1 receptor-mediated internalization of circulating Ang II [19] , but also to changes in the soluble aminopeptidase activities, important for the disposal of Ang peptides in kidney. Discrepancies are observed between SOL and MEMB AlaAP and AspAP activities in their response to the conditions that underlie to this model of hypertension and to valsartan treatment. Although SOL and MEMB activities might hydrolyze the same substrates, the regulatory mechanisms of both enzymatic pools may be independent and local ischemia may determine this differential response, i.e. affecting to the degree of Ang internalization and subsequent metabolism [14] .
In summary, taken together the most significant changes observed in the present work and previous information [17, 20, 21] , it could be hypothesized that in the renal cortex there is an increased formation of Ang II, a reduction in its metabolism and an increased formation of Ang IV in the non-clipped kidney of G2K1C animals. On the other hand, valsartan treatment suggests an increased formation of Ang II together with a decreased metabolism of Ang III in the renal cortex of normal rats and in the clipped kidney of G2K1C animals (Fig. 3) .
The great difference observed for AspAP activity between the renal medulla and the cortex is remarkable. SOL and MEMB AspAP activities were, respectively, four-and five-fold higher in the renal cortex than in medulla in all groups studied. This might indicate their relative functional difference between both locations. Aminopeptidase A (GluAP), by removing the Asp residue, is the enzyme responsible for the rapid metabolism of Ang II [33] . AspAP also cleaves Asp residues but this enzyme is distinct from GluAP, and both enzymes have repeatedly demonstrated their different behavior in kidney and other tissues [22, 23, 32] . Although AspAP had some aminopeptidase A activity, GluAP did not show difference between medulla and cortex [21] . This underlines the functional difference between both enzymes and also suggests differences between renal cortex and medulla in the function of AspAP. AspAP has been described as the enzyme responsible for the metabolism of Ang I to Ang 2-10 [27] . Although the exact mechanisms of action remain to be elucidated, studies suggest that Ang 2-10 act on Ang receptors inducing responses that counteract the actions of Ang II [18] .
In the renal medulla, valsartan did not affect angiotensinase activities either in normal kidneys of Sham-operated or in clipped and non-clipped kidneys of G2K1C animals. Similar to the renal cortex, SOL AlaAP and SOL AspAP decreased in the medulla of the clipped kidney of G2K1C rats. However, in contrast to the renal cortex, MEMB AlaAP decreased in the medulla of the non-clipped kidney of G2K1C rats. This may indicate a lower Ang III metabolism at this location, which may suggest a role for this peptide in the pathogenesis of G2K1C hypertension. This result also indicates that the behavior of AlaAP activity depends on its renal location.
In conclusion, the present results suggest that other angiotensin peptides than Ang II, such as Ang III, Ang IV or Ang 2-10, are involved in the pathogenesis of G2K1C hypertension and in the renal response to the AT 1 blockade with valsartan, these effects being mediated by angiotensinase activity.
